Background and aim of work: Immunomodulatory mediators play a crucial role in the pathogenesis of heart failure (HF). Vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-l (ICAM-1) are important inflammatory mediators of leukocyte adhesion to vascular endothelium and their plasma levles increase in chronic and acute inflammation. Furthermore, the immune modulators CD40 ligand (CD40L) and sFas have been receiving increased attention, since they play a key role in the pathophysiology of multicellular vascular events such as thrombosis, inflammation, and atherosclerosis. Based on the previous facts, we planned to evaluate the role of plasma VCAM-1, ICAM-1, and serum soluble CD40L (sCD40L) and sFas in HF. Subjects and methods: The present study was done on 30 male patients with HF who were classified according to the type of HF to: 15 patients with chronic HF (CHF) due to ischemic causes and 15 patients with acute myocardial infarction (AMI) complicated with HF during acute phase (AHF). Ten age-matched healthy male volunteers were taken as controls. Plasma levels of VCAM-1, ICAM-1, and serum levels of sCD40L and sFas were measured in all groups. Lipid profile, creatine phosphokinase and its MB fraction were also measured. Results: There were significant increase in plasma levels of VCAM-1 (P<0.05), ICAM-1 (P<0.001), and serum levels of sCD40L (P<0.001) and sFas (P<0.001) in both CHF and AHF patients compared to control subjects. There was a significant positive correlation between VCAM-1 and sCD40L, as well as sFas in CHF (r = 0.46, P = 0.03 and r = 0.47, P = 0.02 respectively) and a significant positive correlation between ICAM-1 and sCD40L, as well as sFas in AHF (r = 0.551, P<0.01 and r = 0.49, P = 0.012 respectively). Also, there was a positive significant correlation between sCD40L and low-density lipoprotein cholesterol in both CHF and AHF cases (P<0.05). Conclusion: sCD40L, sFas, VCAM-1, and ICAM-1 could be used as markers that might predict cardiovascular events in patients with chronic and acute heart diseases.
INTRODUCTION
Coronary heart disease is a major cause of hospitalization and mortality worldwide. Chronic inflammation and endothelial activation may be present in patients with heart failure (HF) and may contribute to the pathogenesis and progression of that disease (1) . Cellular adhesion molecules, namely, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), members of immunoglobulin superfamily genes, are poorly expressed by the resting endothelium (2) . They are upregulated during inflammatory atherogenesis and might be an index of endothelial activation or even a molecular marker of early atherosclerosis (3) . A variety of stimuli may impair endothelial function rendering it susceptible to leucocytes adhesion with expression of large amount of VCAM-I and ICAM-I (4) . Each molecule of ICAM-1 (also known as CD154) is characterized by five distinct immunoglobulin-like domains, a transmembrane domain, and cytoplasmic tail. VCAM-1 (also known as CD 106) is a seven domains. In atherosclerosis, it has been shown that ICAM-1 is upregulated in sites prone to atherosclerosis development (5) . Baseline levels of ICAM-1 are increased many years before a first myocardial infarction (MI) occurs (6,7) . CD40 ligand (CD40L), a transmembrane protein structurally related to tumor necrosis factor, was originally identified on CD4 + T cells, and can be expressed by macrophages, T cells, endothelium, and smooth muscle in atherosclerotic lesions in vivo. It has been estimated that more than 95% of the circulating soluble CD40L (sCD40L) is derived from platelets and has been shown to activate endothelium (8) . Both membrane-bound and sCD40L forms of that ligand may interact with CD40, which is constitutively expressed on B (14) .
In the present study, we planned to examine serum levels of sCD40L and sFas, and plasma levels of ICAM-1 and VCAM-1; and their roles in the pathogenesis of coronary heart disease in patients with acute HF (AHF) following MI and chronic HF (CHF) of ischemic origin.
SUBJECTS & METHODS
The study was carried out on 30 male patients who were admitted to Cardiology Department of Zagazig University Hospital and diagnosed as HF, and 10 age-matched normal healthy men volunteers were taken as controls. Patients with HF were classified according to the type of HF to: 15 patients with CHF due to ischemic causes and 15 patients with MI complicated with HF during acute phase (AHF). CHF was defined as dyspnea, fatigue at rest or on exertion for more than 3 months, and The diagnosis of AMI was determined by the finding of typical rise and fall of creatine phosphokinase (CPK)-MB with at least one of the followings criteria: (a) ischemic symptoms, (b) development of pathologic Q waves on the ECG, (c) ECG changes indicating ischemia (ST segment elevation or depression), or coronary arterial intervention (15) . The age of patients with AHF ranged from 47-69 years (mean 58±6 years). The age of CHF patients ranged from 48-71 years (mean 58±8 years). The age of controls ranged from 47-70 years (mean 57±7 years). There were no significant differences as regard age in the three groups.
Eight ml blood sample was withdrawn from each subject after overnight fasting. Blood samples from patients with AHF were collected within the first 24 hours of diagnosis of MI. Plasma samples were used for detection of VCAM-1 and ICAM-1, and serum samples were used for determination of sCD40L, sFas, lipid profile, CPK, and CPK-MB. All samples were stored at -20°C till used.
Plasma 
RESULTS
There were highly significant increase in CPK and CPK-MB activities in patients with AHF as compared to either controls or patients with CHF (P<0.001 in both groups), but there was no statistically significant difference in these parameters between patients with CHF and controls. There were no statistically significant differences between patients with AHF and patients with CHF or either of these groups compared to controls as regard TC, TG, and HDL-C. But; as regard LDL-C, there were highly significant increase the mean serum level in either patients with AHF or patients with CHF compared with controls (P<0.001), and significant increase in patients with AHF compared to patients with CHF (P = 0.02), Table 1 .
There were highly significant increase in the mean plasma levels of VCAM-1 and ICAM-1 and in mean serum levels of sCD40L, and sFas in either patients with AHF or patients with CHF compared with controls, but no significant differences were found in these parameters comparing patients with AHF vs patients with CHF, Table 2 .
Pearson's correlation (r) was done to find relations between the studied parameters in patients with AHF and patients with CHF. In patients with AHF: as regard serum sCD40L, a highly significant positive correlation was found with both TC (r = 0.657, P=0.002) and plasma ICAM-1 (r = 0.551, P<0.003), and a significant positive correlation with plasma VCAM-1 (r = 0.473, P = 0.028) and LDL-C (r = 0.511, P = 0.011), and insignificant correlation with CPK, CPK-MB, TG, HDL-C, and serum sFas; as regard plasma VCAM-1 a significant positive correlation was found only with serum sCD40L and insignificant correlation with other parameters; and as regard plasma ICAM-1 a significant positive correlation was found with TC (r = 0.439, P = 0.040), LDL-C (r = 0.442, P = 0.040), and serum sFas (r = 0.493, P=0.012), and insignificant correlation with CPK, CPK-MB, TG, HDL-C, Table 3 .
In patients with CHF: as regard serum sCD40L, a significant positive correlation was found with TC (r = 0.491, P = 0.014), LDL-C (r = 0.440, P = 0.038), plasma VCAM-1 (r = 0.462, P = 0.028), and plasma ICAM-1 (r = 0.410, P = 0.041), and an insignificant correlation with CPK, CPK-MB, TG, HDL-C, and serum sFas; as regard plasma VCAM-1 a significant positive correlation with serum sFas (r = 0.473, P = 0.021) and insignificant correlation with CPK, CPK-MB, TC, TG, HDL-C, LDL-C, and plasma ICAM-1; and as regard plasma ICAM-1 a significant positive correlation was found only with TG (r = 0.471, P = 0.026) and insignificant correlation with other parameters, Table 4 . 
DISCUSSION
In the present study, the small sample size was due to the critical condition of the patients with AHF, and we chose male patients and excluded female patients to exclude the protective effect of the female sex hormone on coronary heart disease in order to unify the risk factors in the studied subjects.
In the present study, the mean plasma levels of ICAM-1 and VCAM-1 were significantly higher in patients with either AHF or CHF compared to controls, but no significant difference in their mean levels between patients with AHF and patients with CHF. Thus the increase in the cellular adhesion molecules is depending on HF. The extent to which the underlying disease processes of atherosclerosis and cardiomyopathy contribute to the increased plasma level of adhesion molecules in patients with HF is unclear. and Kawakami et al. (1998) (44) have also found plasma sFas were increasing in proportion to the severity of HF. Production of sFas might primarily reflect the activation of cytotoxic lymphocytes which contribute to the development of cardiomyopathy (47, 48) . Accordingly, sFas correlated with the soluble IL-2 receptor, a marker of activated lymphocytes (46) , and was elevated in auto-immune diseases triggered by cytotoxic lymphocytes (12) . In addition to the potential effects of sFas on the myocardium, circulating sFas may also contribute to multi-organ dysfunction in HF patients (49) . High sFas indicated a poor prognosis and reflecting ongoing apoptotic activity and may help to identify high-risk patients who may benefit from an intensified treatment.
CPK and CK-MB were significantly higher in patients with AHF following MI in comparison to patients with CHF or controls and no significant difference was found between patients with CHF vs controls. Because our patients of CHF were of ischemic origin, so the levels of CPK and CK-MB increase in response to MI and do not reflect the coronary ischemia and could not be used as a marker of ischemic heart state. LDL-C is the only parameter of lipid profile that showed significant increase in patients with CHF and in patients with AHF vs controls. Therefore; drugs that lower LDL-C levels may improve the ischemic heart state.
In the current work we found no significant correlation between the three studied inflammatory markers (sCD40L, VCAM-1 and ICAM-1) and markers of myocardial necrosis; CPK, CK-MB in either patients with AHF or patients with CHF. Yoshioka et al., (2010) have found the plasma log CD40L levels in the culprit coronary arteries correlated positively with maximal serum CK-MB after AMI (50) .
In the present study, correlation analysis revealed that serum sCD40L levels were positively associated with plasma levels of both ICAM-1 and VCAM-1, implying that elevated serum adhesion molecules in patients with ischemic heart disease might be related to the increased sCD40L concentrations. These findings are comparable to those of Peng et al. (51) and Tsakiris et al.
(2000) (52) . It could be concluded that the sCD40L, sFas and adhesion molecules (VCAM-1 and ICAM-1) could be used as markers that might predict cardiovascular events in patient with chronic and acute heart diseases as the increase in the VCAM-1, ICAM-1 and CD40L are depending on HF. Moreover, the increase in serum sFas might be related to the pathophysiologic mechanisms of CHF. Therefore, sFas is a promising biomarker in pathophysiological relevance in medical diagnosis of HF and may be possibly a marker for the prognosis of HF treatment. 
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